Literature DB >> 1365672

Imipramine and 2-hydroxyimipramine: comparative cardiotoxicity and pharmacokinetics in swine.

B G Pollock1, J M Perel.   

Abstract

The hemodynamic, cardiographic, and initial pharmacokinetic characteristics of the de novo administration of the 2-hydroxymetabolite (2-OH-IMI) of imipramine (IMI), compared with its parent was studied in a swine preparation. Cardiac output, arterial pressure, and the continuous electrocardiogram were assessed after the intravenous administration of the drug or its metabolite. Plasma, sampled over 120 min and CSF sampled at 60 min were analyzed by reverse phase HPLC with spectroflurometric detection. Equilibrium dialyses were performed on plasma sampled at 60 min. 2-OH-IMI, in doses of 5-6 mg/kg, compared to dosages of IMI up to 8.5 mg/kg, produced a significantly greater incidence of life-threatening arrhythmias, and caused profound and significant decreases in blood pressure and cardiac output. 2-OH-IMI had a smaller volume of distribution (Vd) and shorter half-life. CNS penetration, as estimated by CSF/plasma ratios, was significantly greater for 2-OH-IMI. These phenomena were partly accounted for by significantly less protein binding for the hydroxymetabolite. It is concluded that 2-OH-IMI has increased penetrance into the CNS despite a smaller Vd and that it is significantly more cardiotoxic than its parent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1365672     DOI: 10.1007/bf02245480

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  26 in total

1.  CARDIOVASCULAR EFFECTS OF IMIPRAMINE.

Authors:  E B SIGG; M OSBORNE; B KOROL
Journal:  J Pharmacol Exp Ther       Date:  1963-08       Impact factor: 4.030

Review 2.  Linear relationships between lipophilic character and biological activity of drugs.

Authors:  C Hansch; W J Dunn
Journal:  J Pharm Sci       Date:  1972-01       Impact factor: 3.534

3.  Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.

Authors:  M Ehrnebo; S Agurell; B Jalling; L O Boréus
Journal:  Eur J Clin Pharmacol       Date:  1971-09       Impact factor: 2.953

4.  A pharmacokinetic analysis program (multi) for microcomputer.

Authors:  K Yamaoka; Y Tanigawara; T Nakagawa; T Uno
Journal:  J Pharmacobiodyn       Date:  1981-11

5.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors:  W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

6.  Antiarrhythmic effects of tricyclic antidepressant drugs in ouabain-induced arrhythmias in the dog.

Authors:  R D Wilkerson
Journal:  J Pharmacol Exp Ther       Date:  1978-06       Impact factor: 4.030

7.  Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain.

Authors:  E El-Fakahany; E Richelson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

8.  Inhibition of biogenic amines uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain.

Authors:  J I Javaid; J M Perel; J M Davis
Journal:  Life Sci       Date:  1979-01-01       Impact factor: 5.037

9.  Electrocardiogram changes and therapeutic desipramine and 2-hydroxy-desipramine concentrations in elderly depressives.

Authors:  S P Kutcher; K Reid; J D Dubbin; K I Shulman
Journal:  Br J Psychiatry       Date:  1986-06       Impact factor: 9.319

10.  Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants.

Authors:  M T Boehnert; F H Lovejoy
Journal:  N Engl J Med       Date:  1985-08-22       Impact factor: 91.245

View more
  1 in total

1.  Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine.

Authors:  S Härtter; M Arand; F Oesch; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.